DaVita (DVA)
(Delayed Data from NYSE)
$163.08 USD
+0.82 (0.51%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $162.00 -1.08 (-0.66%) 5:20 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$163.08 USD
+0.82 (0.51%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $162.00 -1.08 (-0.66%) 5:20 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum B VGM
Zacks News
Here's Why You Should Retain Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Product innovations and strategic progress bode well for Tandem Diabetes (TNDM).
Here's Why You Should Add Masimo (MASI) to Your Portfolio Now
by Zacks Equity Research
Masimo's (MASI) R&D activities raise optimism about the stock.
Here's Why You Should Retain Inspire Medical (INSP) Stock Now
by Zacks Equity Research
Inspire Medical's (INSP) focus on R&D raises optimism about the stock.
Revvity's (RVTY) New Launch to Boost Newborn Sequencing Research
by Zacks Equity Research
Revvity's (RVTY) next-generation newborn sequencing research workflow is likely to build the foundation for diagnosing rare diseases in the future.
Waters (WAT) Boosts PFAS Testing Solutions With New Cartridges
by Zacks Equity Research
Waters (WAT) launches Oasis WAX/GCB and GCB/WAX Cartridges for PFAS testing, thus boosting the Waters Operating segment.
High Tide (HITI) Acquires Queen of Bud to Expand Its Portfolio
by Zacks Equity Research
High Tide (HITI) announces the acquisition of Queen of Bud to boost its in-house cannabis brand portfolio without burdening its significant capital expenditure.
Chemed (CHE) Reaches a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Chemed (CHE) on strong performance across the VITAS and Roto-Rooter segments.
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Boston Scientific (BSX) Global Growth Robust, Macro Issues Ail
by Zacks Equity Research
Boston Scientific (BSX) is consistently registering fast recovery within its MedSurg segment in the post-pandemic period.
PetIQ (PETQ) Broadens Minties Line With Large Dogs Dental Treats
by Zacks Equity Research
PetIQ (PETQ), with a focus on affordability and natural ingredients, is well-positioned to meet the evolving needs of pet owners and continue its growth trajectory in the pet wellness market.
Here's Why You Should Buy Insulet (PODD) Stock Right Now
by Zacks Equity Research
Investors remain confident in the Insulet (PODD) stock due to the huge success of Omnipod 5.
Exact Sciences' (EXAS) BLUE-C Study Results Published in NEJM
by Zacks Equity Research
Exact Sciences (EXAS) announces the publication of the BLUE-C study results in The New England Journal of Medicine.
GE HealthCare (GEHC) Advances AI Alliance to Improve Workflow
by Zacks Equity Research
GE HealthCare's (GEHC) evolution of its AI collaboration is likely to lead to digital and AI transformation and provide better patient care and outcomes.
Edwards Lifesciences (EW) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Edwards Lifesciences (EW) outperforms the industry, owing to a robust 2023 fourth-quarter performance, as well as the strong potential in the TMTT division.
Intuitive Surgical's (ISRG) Da Vinci 5 Receives FDA Approval
by Zacks Equity Research
Intuitive Surgical (ISRG) announces the FDA clearance for its next-generation robotic system, da Vinci 5, which is likely to improve surgical workflow and save significant time with better care.
Waters (WAT) Boosts Portfolio Strength With Rheo-IS Accessory
by Zacks Equity Research
Waters (WAT) unveils Rheo-IS accessory for its TA Instruments Discovery Hybrid Rheometers, bolstering its overall portfolio.
Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Labcorp (LH) Expands Strategic Alliances, Test Sales Fall
by Zacks Equity Research
Labcorp (LH) continues to progress in terms of integrating hospital partnerships and acquisitions.
Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System
by Zacks Equity Research
Axonics' (AXNX) fourth-generation rechargeable Sacral Neuromodulation system will reduce the frequency of patient recharges significantly. The new form factor ensures ease of use.
Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Philips (PHG) Expands Sonicare Portfolio With Latest Launch
by Zacks Equity Research
Philips (PHG) adds Philips One for Kids toothbrush into its Sonicare family, boosting its Personal Health business.
BD's (BDX) ADC System Favored by New Study for Long-Term Care
by Zacks Equity Research
BD's (BDX) ADC system is likely to result in improvements in clinical workflow, operational efficiency and financial savings in long-term care facilities.
DaVita HealthCare (DVA) Up 12% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inari Medical's (NARI) ClotTriever Improves Patient Outcome
by Zacks Equity Research
Inari Medical (NARI) announces two-year interim results from the CLOUT registry, which shows a significant improvement in patient's post-thrombotic syndrome and lower rethrombosis-related events.
Envista (NVST) Faces Macroeconomic Challenges, FX Headwind
by Zacks Equity Research
The challenging macroeconomic conditions are resulting in a significant escalation in Envista's (NVST) costs and expenses.